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The prevalence of neurodegenerative 
  diseases, particularly those that affect the 
aged, are predicted to increase rapidly in 
the coming decades. The World Health 
Organization forecasts that dementia cases 
will increase by almost 50% between 2005 
and 2030. Supporting data suggests that the 
predicted number of cases of Alzheimer’s 
disease will quadruple by 2050. It is esti-
mated that interventions that can delay 
disease onset or progression by just 1 year 
would reduce the number of predicted 
cases of Alzheimer’s disease by 9.2 million. 
Unfortunately, current therapies for most 
neurodegenerative diseases are sympto-
matic, and few, if any, disease-modifying 
strategies are available. However, over the 
last few decades there have been consider-
able advances in understanding the trig-
gers of neurodegenerative disease and we 
remain conﬁ  dent that in the coming dec-
ade, new disease modifying strategies will 
be discovered and proven to be effective. 
Nevertheless, several challenges remain in 
the ﬁ  eld that we must overcome to allow 
signiﬁ  cant progress.
To fully elucidate mechanisms of disease, 
it is essential that good model systems are 
available. While cell culture and computer 
modelling have pivotal roles in understand-
ing pathways and interactions, nothing is as 
powerful as an accurate animal model. Many 
transgenic animals, particularly mice, have 
been created to model most major neuro-
degenerative disorders. While these models 
have undoubtedly been of great beneﬁ  t, the 
extent to which they recapitulate the main 
biochemical and behavioural phenotypes 
of disease varies greatly. Perhaps nowhere 
is this more obvious than in Alzheimer’s 
disease research. If you follow the amy-
loid cascade hypothesis, as many do, then 
an increase in Aβ production/deposition 
should evoke several signalling cascades 
resulting in abnormal tau processing and 
neuronal death. Yet, the majority of mice 
genetically altered to over-produce Aβ do 
not show signiﬁ  cant tau pathology, and 
have relatively little neurodegeneration. Is 
this simply because mice do not live long 
enough to develop tau pathology and the 
associated neuronal death? Or are we sim-
ply missing something? A similar prob-
lem is true for Parkinson’s disease models 
where the genetic manipulation of several 
known disease-associated genes, including 
DJ-1, parkin and α-synuclein, often fails 
to reproduce the selective vulnerability of 
dopaminergic neurons in the nigrostri-
atal pathway. With increasing use of more 
advanced transgenic technology, particu-
larly cell- and tissue-type expression and 
knock-out of genes with cre-lox technology, 
we remain hopeful that models that more 
faithfully recapitulate human disease will 
be developed.
Another important issue in the ﬁ  eld 
of neurodegeneration research is that we 
need to fully understand the involvement 
of protein aggregation in disease progres-
sion. Aggregation is a complex process in 
most neurodegenerative diseases, involv-
ing phosphorylation, conformational 
changes, protein truncation by proteases, 
polymerisation, and several other modi-
ﬁ  cations. Aggregates are common to most 
neurodegenerative disorders, presenting as 
neuroﬁ  brillary tangles and senile plaques 
in Alzheimer’s disease, Lewy bodies con-
taining α-synuclein in Parkinson’s disease, 
ubiquitinated protein aggregates in motor 
neuron disease, and accumulations of trun-
cated huntingtin protein in Huntington’s 
disease. Despite years of intensive research, 
it remains unclear whether protein aggre-
gates exert toxic properties, or if their for-
mation is a protective response by neurons 
as they attempt to minimise the inﬂ  uence 
of excess abnormally processed proteins. 
Several studies in models of Alzheimer’s 
and amyotrophic lateral sclerosis have 
suggested that aggregate formation can 
be dissociated from neuronal death, and 
that early, pre-aggregate forms of proteins 
may be more neurotoxic than aggregated 
inclusions. Indeed, soluble monomeric and 
oligomeric protein species are believed to 
be more closely associated with neurode-
generation in several diseases. Determining 
which protein species have inherent toxic-
ity is especially important when considering 
the large number of therapeutic strategies 
aimed at reducing aggregate load that are 
currently being developed. It is entirely pos-
sible that dis-aggregating potentially inert 
disease-associated proteins may increase 
the amount of toxic pre-aggregated soluble 
oligomers, thereby worsening rather than 
preventing disease progression. Therefore, 
it is vital that we further our understanding 
of the various abnormal forms of proteins 
that are generated during the development 
of disease, to ensure that appropriate thera-
peutic avenues are followed.
The spread of pathology in neurodegen-
erative diseases has recently been proposed 
to occur by prion-like transmission. Indeed, 
Aβ, tau and α-synuclein are reported to 
share key biophysical and biochemical 
characteristics with prions. For exam-
ple, ‘seeding’ has been reported in several 
neurodegenerative diseases, where trun-
cated tau species and mutant α-synuclein 
apparently act as a nucleation centre for the 
aggregation of their full-length or wild-type 
counterparts. Furthermore, in typical prion 
diseases, it is believed that the conformation 
of prion proteins is largely responsible for 
the different disease phenotypes observed. 
Perhaps this is also true in fronto-temporal 
dementias associated with tau mutations 
on chromosome-17, for which heterog-
enous phenotypes have been reported. It 
is possible that further exploration of the 
prion-like properties of disease-associated 
proteins may elucidate the mechanisms by 
which neurodegenerative disease pathology 
spreads. This is still a poorly understood 
aspect of this ﬁ  eld of research, which is 
perhaps surprising since selective neuro-
nal vulnerability, and the distribution of 
pathology during disease progression, has 
been widely studied and reported for most 
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disease mechanisms and progression, and 
may in the future lead to individually tai-
lored therapeutic interventions. Although 
there are some technical challenges yet to be 
overcome in this area of research, it seems 
clear that the manipulation of iPSCs may 
represent a powerful new strategy for the 
treatment of neurodegenerative diseases.
In summary, the ﬁ  eld of neurodegenera-
tive disease research has made enormous 
strides in recent decades. However, the chal-
lenge for the future will be the ability to 
utilise our new found knowledge to develop 
better tools and novel therapeutic strate-
gies. Importantly, we need better methods 
to identify people who are at high risk of 
developing neurodegenerative disease 
through the use of sensitive and speciﬁ  c 
biomarkers. Equally, we require more effec-
tive therapies that can reduce neuronal loss 
and prevent disease progression, perhaps by 
taming stem cells to regenerate damaged 
central nervous systems, by immunization, 
or through more conventional pharmaco-
logical approaches.
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Personalized medicine is a long term goal of 
the medical ﬁ  eld and it is becoming increas-
ingly obvious that that genetic background 
and environmental inﬂ  uences will now have 
to be taken into consideration when design-
ing new clinical trials. Indeed, investigations 
of new treatments in pre-clinical laboratory 
studies should perhaps also be designed to 
include several background strains of mice 
since this would provide valuable insight 
into any potential inﬂ  uences of genetic vari-
ability. Another important aspect of clini-
cal research that requires further research is 
the effectiveness of combination therapies. 
For example, there appears to be a syner-
gistic relationship between tau and Aβ in 
Alzheimer’s disease, so perhaps a treatment 
that reduces amyloid load should be used 
together with a tau- directed approach, and/
or anti- inﬂ  ammatory agents, for maximum 
efﬁ  cacy.
Finally, stem cell therapies have shown 
some promise for the treatment of neuro-
degenerative diseases. The central nervous 
system, unlike many other tissues, has a very 
limited capacity for self-repair, although 
there are populations of endogenous neural 
stem cells in speciﬁ  c brain regions. Perhaps 
the greatest recent advance in this area is 
the use of induced pluripotent stem cells 
(iPSCs). The discovery that ﬁ  broblasts can 
be re-programmed to pluripotency and then 
differentiated into speciﬁ  c neuronal sub-
types has wide-spread implications for the 
ﬁ  eld. Obtaining ﬁ  broblasts from skin biop-
sies of patients with neurodegenerative dis-
eases will allow the study of patient- speciﬁ  c 
From a clinical perspective, it is clear 
that more reliable and speciﬁ  c biomarkers 
of disease are needed. These would allow 
the rapid diagnosis of neurodegenerative 
conditions while they are most amenable 
to treatment, and would permit the moni-
toring of disease progression, particularly 
important when assessing the efﬁ  cacy of 
new treatments. However, this has proven 
to be problematic. Most neurodegenera-
tive diseases are complex, involving several 
proteins, often with accompanying neu-
roinﬂ  ammation, and with varying ages of 
onset and speed of progression. In addition, 
there is often overlap between the types of 
pathology observed in distinct diseases. 
Furthermore, it is relatively common for 
two or more neurodegenerative diseases to 
co-occur. Proteomic analysis is increasingly 
used as an unbiased approach to identify 
disease markers. Such screening, in combi-
nation with neuroimaging and additional 
diagnostic testing may enable the future 
development of sensitive and speciﬁ  c 
biomarkers of neurodegenerative diseases. 
It will also be important for such studies to 
follow patients until autopsy so that their 
ﬁ  ndings can be fully validated using post-
mortem tissue.
Another important aspect when con-
sidering treatment is genetic proﬁ  le. It has 
become clear in recent years: that a persons 
genetic proﬁ  le will alter how they respond 
to drug treatments. This was notably 
recorded in recent Alzheimer’s disease tri-
als where persons carrying the apoE4 allele 
did not respond to therapeutic intervention. 